Rocking cell metabolism: Revised functions of the key glycolytic regulator PKM2 in cancer

Trends in Biochemical Sciences

Volumn 37, Issue 8, 2012, Pages 309-316

  Chaneton, Barbara ^a   Gottlieb, Eyal ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; Cancer metabolism; Cancer therapeutics; PKM2; Pyruvate kinase

Indexed keywords

BETA CATENIN; CYCLIN D1; ENOLASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOGLYCERATE MUTASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; PYRUVATE KINASE; PYRUVATE KINASE M1; PYRUVATE KINASE M2; PYRUVATE KINASE M2 INHIBITOR; REACTIVE OXYGEN METABOLITE; SHIKONIN; STAT3 PROTEIN; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CATALYSIS; CELL METABOLISM; CELL NUCLEUS; CELL PROLIFERATION; COMPLEX FORMATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; GENE EXPRESSION; GLYCOLYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

CARRIER PROTEINS; CELL NUCLEUS; CELL PROLIFERATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; THYROID HORMONES; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84864292789     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2012.04.003     Document Type: Review

References (69)

1. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 2011, 43:969-980.
2. Harada K., et al. Purification of four pyruvate kinase isozymes of rats by affinity elution chromatography. Biochim. Biophys. Acta 1978, 524:327-339.
3. Noguchi T., et al. The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J. Biol. Chem. 1987, 262:14366-14371.
4. Noguchi T., et al. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem. 1986, 261:13807-13812.
5. Yamada K., Noguchi T. Nutrient and hormonal regulation of pyruvate kinase gene expression. Biochem. J. 1999, 337:1-11.
6. Bennet M.J., et al. Fetal forms of pyruvate kinase isoenzymes in tumours of the human nervous system. Neuropathol. Appl. Neurobiol. 1975, 1:347-356.
7. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
8. Frezza C., Gottlieb E. Mitochondria in cancer: not just innocent bystanders. Semin. Cancer Biol. 2009, 19:4-11.
9. Frezza C., et al. Inborn and acquired metabolic defects in cancer. J. Mol. Med. (Berl.) 2011, 89:213-220.
10. Mazurek S., et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 2005, 15:300-308.
11. Mazurek S., et al. Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism. Anticancer Res. 2007, 27:3963-3971.
12. Zwerschke W., et al. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:1291-1296.
13. Mazurek S., et al. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J. Bioenerg. Biomembr. 1997, 29:315-330.
14. Clower C.V., et al. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1894-1899.
15. Chen M., et al. Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res. 2010, 70:8977-8980.
16. David C.J., et al. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010, 463:364-368.
17. Asai Y., et al. Insulin stimulates expression of the pyruvate kinase M gene in 3T3-L1 adipocytes. Biosci. Biotechnol. Biochem. 2003, 67:1272-1277.
18. Discher D.J., et al. Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J. Biol. Chem. 1998, 273:26087-26093.
19. Luo W., et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011, 145:732-744.
20. Sun Q., et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4129-4134.
21. Hathurusinghe H.R., et al. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Ann. Surg. Oncol. 2007, 14:2714-2720.
22. Christofk H.R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
23. Hacker H.J., et al. Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis 1998, 19:99-107.
24. Steinberg P., et al. Expression of pyruvate kinase M2 in preneoplastic hepatic foci of N-nitrosomorpholine-treated rats. Virchows Arch. 1999, 434:213-220.
25. Koss K., et al. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. J. Clin. Pathol. 2004, 57:1156-1159.
26. Brinck U., et al. L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virchows Arch. 1994, 424:177-185.
27. Bluemlein K., et al. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2011, 2:393-400.
28. Imamura K., Tanaka T. Multimolecular forms of pyruvate kinase from rat and other mammalian tissues. I. Electrophoretic studies. J. Biochem. 1972, 71:1043-1051.
29. Tsutsumi H., et al. Expression of L- and M-type pyruvate kinase in human tissues. Genomics 1988, 2:86-89.
30. Mazurek S., et al. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene 2001, 20:6891-6898.
31. Eigenbrodt E., et al. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res. 1997, 17:3153-3156.
32. Cerwenka H., et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res. 1999, 19:849-851.
33. Oremek G.M., et al. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. Anticancer Res. 1997, 17:3031-3033.
34. Oremek G.M., et al. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res. 1999, 19:2599-2601.
35. Ashizawa K., et al. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. J. Biol. Chem. 1991, 266:16842-16846.
36. Kato H., et al. Cytosolic thyroid hormone-binding protein is a monomer of pyruvate kinase. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:7861-7865.
37. Dombrauckas J.D., et al. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005, 44:9417-9429.
38. Gao X., et al. Pyruvate kinase m2 regulates gene transcription by acting as a protein kinase. Mol. Cell 2012, 45:598-609.
39. Imamura K., Tanaka T. Multimolecular forms of pyruvate kinase from rat and other mammalian tissues. I. Electrophoretic studies. J. Biochem. 1972, 71:1043-1051.
40. Wooll J.O., et al. Structural and functional linkages between subunit interfaces in mammalian pyruvate kinase. J. Mol. Biol. 2001, 312:525-540.
41. Bailey E., et al. Regulation of rat liver pyruvate kinase. The effect of preincubation, pH, copper ions, fructose 1,6-diphosphate and dietary changes on enzyme activity. Biochem. J. 1968, 108:427-436.
42. Ashizawa K., et al. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. J. Biol. Chem. 1991, 266:16842-16846.
43. Imamura K., et al. Multimolecular forms of pyruvate kinase. II. Purification of M 2 -type pyruvate kinase from Yoshida ascites hepatoma 130 cells and comparative studies on the enzymological and immunological properties of the three types of pyruvate kinases, L, M 1, and M 2. J. Biochem. 1972, 72:1001-1015.
44. Eigenbrodt E., et al. Structural and kinetic differences between the M2 type pyruvate kinases from lung and various tumors. Biomed. Biochim. Acta 1983, 42:S278-S282.
45. Dabrowska A., et al. Interaction of M1 and M2 isozymes pyruvate kinase from human tissues with phospholipids. Biochim. Biophys. Acta 1998, 1383:123-129.
46. Presek P., et al. Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus. FEBS Lett. 1988, 242:194-198.
47. Mazurek S., et al. Studies on associations of glycolytic and glutaminolytic enzymes in MCF-7 cells: role of P36. J. Cell. Physiol. 1996, 167:238-250.
48. Mazurek S., et al. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem. J. 2001, 356:247-256.
49. Christofk H.R., et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452:181-186.
50. Plas D.R., Thompson C.B. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005, 24:7435-7442.
51. Hitosugi T., et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2009, 2:ra73.
52. Boles E., et al. Characterization of a glucose-repressed pyruvate kinase (Pyk2p) in Saccharomyces cerevisiae that is catalytically insensitive to fructose-1,6-bisphosphate. J. Bacteriol. 1997, 179:2987-2993.
53. Gruning N.M., et al. Pyruvate kinase triggers a metabolic feedback loop that controls redox metabolism in respiring cells. Cell Metab. 2011, 14:415-427.
54. Anastasiou D., et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334:1278-1283.
55. Wang Q., et al. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 2010, 327:1004-1007.
56. Lv L., et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 2011, 42:719-730.
57. Stetak A., et al. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res. 2007, 67:1602-1608.
58. Hoshino A., et al. Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J. Biol. Chem. 2007, 282:17706-17711.
59. Spoden G.A., et al. The SUMO-E3 ligase PIAS3 targets pyruvate kinase M2. J. Cell. Biochem. 2009, 107:293-302.
60. Yang W., et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011, 480:118-122.
61. Lee J., et al. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int. J. Biochem. Cell Biol. 2008, 40:1043-1054.
62. Spoden G.A., et al. Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int. J. Cancer 2008, 123:312-321.
63. Vander Heiden M.G., et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 2010, 79:1118-1124.
64. Porporato P.E., et al. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front. Pharmacol. 2011, 2:49.
65. Chen J., et al. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 2011, 30:4297-4306.
66. Boxer M.B., et al. Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J. Med. Chem. 2010, 53:1048-1055.
67. Jiang J.K., et al. Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 2010, 20:3387-3393.
68. Walsh M.J., et al. 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 2011, 21:6322-6327.
69. Hansen S. Powering down cancer. BioCentury, the Bernstein Report on BioBusiness 2011, 19:A8.